Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Arzerra receives approval in Japan
Teva Presents New Data Which Demonstrate Reduction of Injection-Related Adverse Events with the Less Frequent Dosing of Three-times-a-week COPAXONE® (glatiramer acetate injection) 40 mg Compared to Daily COPAXONE® 20 mg
Gilenya prescribing information
Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years.
Development of the Brief Inventory of Perceived Stress.
Progress in multiple sclerosis research in the last year.
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.
Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study.
Reduction of inflammation and preservation of neurological function by anti-CD52 therapy in murine experimental autoimmune encephalomyelitis.
Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies.
Liposarcoma concurrence in a multiple sclerosis patient treated with interferon-beta 1b.
Glatiramer acetate (copaxone) modulates platelet activation and inhibits thrombin-induced calcium influx: possible role of copaxone in targeting platelets during autoimmune neuroinflammation.
Patients with migraine do not have MRI-visible cortical lesions.
Mycoplasma pneumonia seroposivity in Iranian patients with relapsing-remitting multipl sclerosis: a randomized case-control study.
Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy.
Predictors of quality of life among multiple sclerosis patients: a comprehensive analysis.
Lymphomatoid papulosis type D in a fingolimod-treated multiple sclerosis patient.
Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis.
Pharmaceutical approval update.
First NW patient to receive OHSU/VAMC-invented MS drug
Conformational Landscape of N-Glycosylated Peptides Detecting Autoantibodies in Multiple Sclerosis, Revealed by Hamiltonian Replica Exchange.
Amiloride Clinical Trial In Optic Neuritis (ACTION) protocol: a randomised, double blind, placebo controlled trial.
Pregnancy level of estrogen attenuates experimental autoimmune encephalomyelitis in both ovariectomized and pregnant C57BL/6 mice through expansion of Treg and Th2 cells.
A phase II study of laquinimod in Crohn's disease.
Neural differentiation of patient specific iPS cells as a novel approach to study the pathophysiology of multiple sclerosis.

Pages